We continuously employ our powerful drug-discovery and computational tools to identify and target drivers, or critical “pressure points”, in key pathways of disease. We employ big data and proprietary computational algorithms to analyze human disease tissues and couple this with cutting-edge small molecule drug discovery technologies.
One program that resulted from our integrated approach to drug discovery focuses on ubiquitin specific protease 7 (USP7). USP7 is an enzyme that removes a tag called ubiquitin from proteins and stabilizes the levels of those proteins in the cell. USP7 impacts several important cancer pathways, changing the levels of oncogenes and tumor suppressors including p53 and modulating the immune system through targets such as Tip60 and FoxP3.